Insider · CIK 0001818068

Brenner Malcolm

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001818068

Forms 4 and 5

Insider transactions

43 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-06-06	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+35K sh	—	—	100,197
2023-05-11	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+35K sh	—	—	65,197
2022-05-17	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.5K sh	—	—	27,500
2021-05-25	KLRSKalaris Therapeutics, Inc.G Gift	Director	GGift	−819K sh	—	—	0
2021-05-25	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2021-03-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−6,141 sh	$32.19	−$198K	821,664
2021-03-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−23.7K sh	$30.39	−$719K	843,094
2021-03-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−15.3K sh	$31.27	−$478K	827,805
2021-03-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,300 sh	$33.31	−$76.6K	819,364
2021-03-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−701 sh	$34.40	−$24.1K	818,663
2021-03-04	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−16K sh	$34.67	−$553K	900,391
2021-03-04	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−8,814 sh	$36.58	−$322K	877,701
2021-03-04	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−13.9K sh	$35.46	−$492K	886,515
2021-03-04	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−10.9K sh	$37.41	−$410K	866,754
2021-03-03	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−8,500 sh	$38.53	−$327K	916,352
2021-03-03	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−6,032 sh	$37.73	−$228K	924,852
2021-03-03	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−3,383 sh	$36.91	−$125K	930,884
2021-03-02	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−3,727 sh	$37.35	−$139K	943,198
2021-03-02	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−7,317 sh	$38.27	−$280K	935,881
2021-03-02	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,614 sh	$39.14	−$63.2K	934,267
2021-03-01	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−8,869 sh	$39.00	−$346K	946,925
2021-03-01	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−12.8K sh	$38.39	−$492K	955,794
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,801 sh	$40.40	−$72.8K	968,819
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−200 sh	$41.19	−$8,238	968,619
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−3,688 sh	$39.46	−$146K	970,620
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,800 sh	$38.75	−$108K	974,308
2021-02-22	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,334 sh	$41.58	−$97.1K	986,197
2021-02-22	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−310 sh	$43.38	−$13.4K	977,108
2021-02-22	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−8,779 sh	$42.80	−$376K	977,418
2021-02-19	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−12K sh	$41.78	−$501K	988,531
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,982 sh	$41.49	−$124K	1,000,521
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−975 sh	$39.68	−$38.7K	1,006,303
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,800 sh	$40.34	−$113K	1,003,503
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−200 sh	$41.99	−$8,398	1,007,278
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,200 sh	$38.66	−$46.4K	1,011,243
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$39.97	−$40K	1,010,243
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−2,765 sh	$41.29	−$114K	1,007,478
2021-02-16	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$42.25	−$42.2K	1,012,543
2021-02-16	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−5,120 sh	$41.75	−$214K	1,013,543
2021-02-16	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−100 sh	$43.13	−$4,313	1,012,443
2020-08-03	KLRSKalaris Therapeutics, Inc.C Conversion	Director	CConversion	+1.02M sh	—	—	1,018,663
2020-08-03	KLRSKalaris Therapeutics, Inc. · Series A-3 Convertible Preferred StockC Conversion	Director	CConversion	−1.52M sh	—	—	0
2020-07-29	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500

Recent filings

Accepted (ET)
Jun 74
Brenner Malcolm0000950170-24-070591
SEC(opens sec.gov)
May 124
Brenner Malcolm0001209191-23-029098
SEC(opens sec.gov)
May 194
Brenner Malcolm0000899243-22-018833
SEC(opens sec.gov)
May 274
Brenner Malcolm0000899243-21-020866
SEC(opens sec.gov)
Mar 84
Brenner Malcolm0001209191-21-018532
SEC(opens sec.gov)
Mar 34
Brenner Malcolm0001209191-21-017524
SEC(opens sec.gov)

Companies

Kalaris Therapeutics, Inc.DirectorKLRS

Address

C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500

CAMBRIDGE, MA, 02142